Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sb-203580. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 16/20 | 0.73 |
| ▸ | PRKD3 known ✓ | O94806 | 4/20 | 0.73 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.65 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.65 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 0.65 |
| ▸ | LCK known ✓ | P06239 | 2/20 | 0.65 |
| ▸ | ERBB4 known ✓ | Q15303 | 2/20 | 0.65 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.65 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.65 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.62 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.62 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.62 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.62 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 0.62 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.62 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.62 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.62 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.62 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.62 |
| ▸ | PRKCH known ✓ | P24723 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-203580 SCHEMBL146399 | 0.99 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL220990 | 0.99 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL95208 | 0.99 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL25800837 | 0.99 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| Sb-203580 SCHEMBL27075368 | 0.99 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL9192799 | 0.99 | MAPK11 (0.75) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL20335254 | 0.89 | MAPK11 (0.79) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6447875 | 0.88 | MAPK13 (0.72) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL1389121 | 0.86 | MAPK14 (0.67) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6606221 | 0.86 | MAPK11 (0.70) | MAPK11MAPK14MAPK13MAPK12GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-20250302883-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| CN-119790137-A | Human nasal organoids and methods of making and using the same | 港大科桥有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20240408145-A1 | Gene Therapy | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-12-12 | — | — | US | disclosed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | disclosed |
| EP-4419543-A1 | GENE THERAPY | Ospedale San Raffaele S.r.l. (IT) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024150014-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2024-07-18 | — | — | WO | disclosed |
| CN-112567023-B | Mature airway organoids, methods of making and uses thereof | 香港大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-118076727-A | Alveolar organoids and methods of making and using the same | 港大科桥有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11971402-B2 | Methods and reagents for determination and treatment of organotropic metastasis | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11890286-B2 | Methods and compositions for treating cancer | THE UNIVERSITY OF CHICAGO (US) | 2024-02-06 | — | — | US | disclosed |
| CN-116942832-A | Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus | 归属疗法有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023066735-A1 | GENE THERAPY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-04-27 | — | — | WO | disclosed |
| US-20230057984-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2023-02-23 | — | — | US | disclosed |
| US-10813920-B2 | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage | THE DOSHISHA (JP) | 2020-10-27 | — | — | US | disclosed |
| US-20080119498-A1 | Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408145-A1 | Gene Therapy | MCL1, DNASE1L3, CDKN1A | MAPK14 4027/4885PRKD3 2810/4885EGFR 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.